Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: death (secondary outcome) compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Adverse events: all ‐ central nervous system events (e.g. headache, seizures) (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: all ‐ central nervous system events (e.g. headache,… compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Adverse events: all ‐ other events ‐ not listed above (e.g. dysuria, neck pain, eye discomfort) (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: all ‐ other events ‐ not listed above (e.g.… compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Overall survival · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Disease-free survival · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Resectability · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Quality of life · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Adverse events · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Complete remission · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Partial reduction · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Recurrence · Patients with a pathological diagnosis of central giant cell granuloma (CGCG) of the jaws
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Stress symptoms ( · healthcare workers
3 findings from 1 review
no estimate extracted
35 studies · 2366 participants
Low
no estimate extracted
6 studies · 427 participants
Low
no estimate extracted
0 studies · 0 participants
GRADE not reported
Children's percentage of total energy intake from saturated fat Measured by food frequency questionnaire and 24‐hour recall · children aged 4 to 14 years
1 finding from 1 review
Children's sodium intake (mg/d) Measured by 24‐hour recall · children aged 4 to 14 years
1 finding from 1 review
Children's fruit and vegetable intake (servings/d) Measured by food frequency questionnaire · children aged 4 to 14 years
1 finding from 1 review
Children's SSB intake (SSB drinks/d, soft drink glasses/d and regular soda servings/d) Measured by questionnaires · children aged 4 to 14 years
1 finding from 1 review
Physical activity · children aged 4 to 14 years
1 finding from 1 review
Children's MVPA (min/d) Measured by questionnaire · children aged 4 to 14 years
1 finding from 1 review
Seizure freedom · people with focal epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people with focal epilepsy
Immunomodulatory interventions probably leads to higher 50% or greater reduction in seizure frequency ‐ ITT analysis compared with placebo (moderate certainty).
1 finding from 1 review